IRCT20190726044339N1 IRCT 2020-12-12 Shiraz University of Medical Sciences The effect of berberine on the symptoms of patients with schizophrenia The effect of berberine alkaloid on positive and negative symptoms in patients with schizophrenia: a randomized placebo-controlled double-blind clinical trial 2020-12-05 anticipated 60 Complete https://irct.ir/trial/52657 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The researcher will enrolled participants based on convenience sampling method. NCSS software (Number Cruncher Statistical System) and block randomization method will use for randomization the study. In the block randomization method, participants will categorize into 6 blocks (AABB, ABAB, BBAA, BABA, ABBA, BAAB), each block containing 4 participants. In this study, "A" will assign to the drug group and "B" to the placebo group, for example: in the "ABAB" block, the first person entered the drug group, the second person entered the placebo group, the third person entered the drug group, and the fourth person entered the placebo group. Thus, all eligible participants will randomly assigned to one of the study arms according to the randomization list, Blinding description: Physicians, patients, and drug deliverer will blind to the allocation of intervention. It should be noted that the drugs' containers is the same. Additionally, placebo capsule is similar to beriberine capsule regarding the color and shape. 2-3 Schizophrenia. Intervention 1: Intervention group: Risperson 2 to 6 mg daily with one berberine capsule daily for a month. Intervention 2: Control group: Risperson 2 to 6 mg daily with one placebo capsule daily for a month. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is It is not yet known if there will be a plan to make this available